This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Robbert Gerrit Van Der Most: Innovator in Immunogenic Composition
Introduction
Robbert Gerrit Van Der Most is a notable inventor based in Rixensart, Belgium. He has made significant contributions to the field of immunology, particularly in the development of methods for inducing immune responses. With a total of 2 patents, his work is recognized for its innovative approaches to immunogenic compositions.
Latest Patents
Van Der Most's latest patents focus on methods for inducing an immune response. One patent describes methods comprising at least two administrations of an adjuvanted immunogenic composition, where the second administration contains reduced amounts of antigen and adjuvant. Another patent outlines methods and uses for inducing an immune response that involve administering a lower dose in the second administration compared to the first, with the possibility of the second administration being unadjuvanted.
Career Highlights
Robbert Gerrit Van Der Most is associated with GlaxoSmithKline Biologicals SA, a leading company in the pharmaceutical industry. His work at this organization has allowed him to contribute to advancements in vaccine development and immunotherapy.
Collaborations
Some of his notable coworkers include Arnaud Michel Didierlaurent and William Ripley Ballou, Jr. Their collaboration has likely enhanced the research and development efforts in the field of immunology.
Conclusion
Robbert Gerrit Van Der Most is a distinguished inventor whose work in immunogenic compositions has the potential to impact vaccine development significantly. His innovative methods for inducing immune responses demonstrate his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
